Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
As of today (2026-07-21), the Trailing Annual Dividend Yield of Hikma Pharmaceuticals is 0.00%.
The historical rank and industry rank for Hikma Pharmaceuticals's Dividend Yield % or its related term are showing as below:
During the past 13 years, the highest Dividend Yield of Hikma Pharmaceuticals was 5.20%. The lowest was 0.65%. And the median was 1.98%.
DIFX:HIK's Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.92 * Ranked among companies with meaningful Dividend Yield % only.
During the past 12 months, Hikma Pharmaceuticals's average Dividends Per Share Growth Rate was 1.00% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was 13.20% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was 14.00% per year.
During the past 10 years, the average Dividends Per Share Growth Rate was 12.80% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Hikma Pharmaceuticals was 38.40% per year. The lowest was 8.90% per year. And the median was 15.70% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Hikma Pharmaceuticals Dividend Yield % Related Terms
Hikma Pharmaceuticals Dividend Yield % Historical Data
* Premium members only.
The historical data trend for Hikma Pharmaceuticals's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DIFX:HIK vs ZTS, UTHR, VTRS: Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hikma Pharmaceuticals Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Hikma Pharmaceuticals's Dividend Yield % falls into.
Hikma Pharmaceuticals (DIFX:HIK) has a Dividend Yield % of 0.00% as of Jul. 21, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Hikma Pharmaceuticals and its competitors. Over the past decade, Hikma Pharmaceuticals' Dividend Yield % has ranged from 0.65 to 5.20. According to the industry distribution chart, Hikma Pharmaceuticals ranks #96 out of 513 companies in the Drug Manufacturers industry, placing it in the top 18.7%.
Is Hikma Pharmaceuticals' Dividend Yield % too high?
Hikma Pharmaceuticals' current Dividend Yield % is 0.00%. Over the past 10 years, this metric has ranged from a low of 0.65 to a high of 5.20. Based on the distribution chart, Hikma Pharmaceuticals ranks #96 out of 513 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hikma Pharmaceuticals has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' Dividend Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hikma Pharmaceuticals ranks #96 out of 513 companies for Dividend Yield %. This places Hikma Pharmaceuticals in the top 19% of its industry — outperforming the majority of peers. The industry median Dividend Yield % is 1.92. Historically, Hikma Pharmaceuticals' own Dividend Yield % has ranged from 0.65 to 5.20 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Drug Manufacturers company?
The median Dividend Yield % among Drug Manufacturers companies is 1.92, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Hikma Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Dividend Yield % is 1.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hikma Pharmaceuticals's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Hikma Pharmaceuticals (DIFX:HIK) has a current Dividend Yield % of 0.00%. The stock's GF Value™ is $14.00, compared to a current price of $10.23 — trading 26.9% below its estimated fair value. The current Dividend Yield % is 0.00%. Hikma Pharmaceuticals' overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Hikma Pharmaceuticals (DIFX:HIK), the current Dividend Yield % is 0.00% as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hikma Pharmaceuticals (DIFX:HIK) Overvalued in 2026?
Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued.
The current stock price of $10.23 is trading 26.9% below its estimated GF Value™ of $14.00.
Key valuation signals for DIFX:HIK:
Dividend Yield %: 0.00%
GF Value™: $14.00 vs. price of $10.23 (26.9% below fair value)
No single metric tells the full story. See the DIFX:HIK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
79GF Score
Get the complete analysis for DIFX:HIK
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DIFX:HIK has been successfully added to your 
